Neutralization of tumor necrosis factor in preclinical models of sepsis.
about
Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failureIs boosting the immune system in sepsis appropriate?The proinflammatory role of HECTD2 in innate immunity and experimental lung injuryT cells down-regulate macrophage TNF production by IRAK1-mediated IL-10 expression and control innate hyperinflammationThe next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*.The "genomic storm" induced by bacterial endotoxin is calmed by a nuclear transport modifier that attenuates localized and systemic inflammationEffects of some acupoints (Du-14, Li-11, St-36, and Sp-6) on serum TNF-α and hsCRP levels in healthy young subjectsAntitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis.Genomic responses in mouse models greatly mimic human inflammatory diseases.Role of tumor necrosis factor-α in the human systemic endotoxin-induced transcriptome.Calcium/calmodulin-dependent protein kinase (CaMK) Ialpha mediates the macrophage inflammatory response to sepsisImmune unresponsiveness to secondary heterologous bacterial infection after sepsis induction is TRAIL dependentThe use of systematic reviews and reporting guidelines to advance the implementation of the 3Rs.Selective improvement of tumor necrosis factor capture in a cytokine hemoadsorption device using immobilized anti-tumor necrosis factor.Protection against TNFα-dependent liver toxicity by intraperitoneal liposome delivered DsiRNA targeting TNFα in vivoShould preclinical studies be registered?n-Butanol extract from Folium isatidis inhibits lipopolysaccharide-induced inflammatory cytokine production in macrophages and protects mice against lipopolysaccharide-induced endotoxic shock.The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of deathCould Biomarkers Direct Therapy for the Septic Patient?Sepsis modeling in mice: ligation length is a major severity factor in cecal ligation and punctureShedding of tumor necrosis factor receptor 1 induced by protein A decreases tumor necrosis factor alpha availability and inflammation during systemic Staphylococcus aureus infection.Inhibition of IKKβ in enterocytes exacerbates sepsis-induced intestinal injury and worsens mortality.Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.The PIRO (predisposition, insult, response, organ dysfunction) model: toward a staging system for acute illness.Genetics and genomics in pediatric septic shock.Insights and limits of translational research in critical care medicine.Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment?Host defenses to Rickettsia rickettsii infection contribute to increased microvascular permeability in human cerebral endothelial cells.Gemfibrozil attenuates the inflammatory response and protects rats from abdominal sepsis.Protective effects of heme oxygenase-1 against severe acute pancreatitis via inhibition of tumor necrosis factor-α and augmentation of interleukin-10.Bridging lipid metabolism and innate host defense.Antimicrobial cathelicidin peptide LL-37 inhibits the pyroptosis of macrophages and improves the survival of polybacterial septic mice.Anti-TNF-α therapy for patients with sepsis: a systematic meta-analysis.Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsis.Potential Immunotherapeutics for Immunosuppression in Sepsis.
P2860
Q26749027-6D41A92D-DC8B-488B-B0C2-631B51D458B3Q27691996-87F1C874-6478-4DD4-A8EC-3248693B5BEEQ28383410-AE3FCA4A-378D-41FA-A21D-C08193E74C08Q28504567-B48A47BF-E615-4BD7-9B34-D6913C707E89Q34057044-AD466119-79FA-424E-AE0B-AE731A0FD531Q34374054-E50096C1-0ACA-4677-9EFE-4772755D4E78Q34805959-4CEA1E47-D93B-4E93-B452-78416755170FQ34866465-8A619C22-58B1-4404-9EB0-9EC4FB156856Q35037958-1F8111D6-899E-4752-83B7-A59818E40229Q35043680-B54B11FD-5D6A-4D1A-9475-5B00F850F41AQ35096741-6723260B-7C62-41ED-A1F2-8469DB600647Q35175936-B41B632F-4F8F-4C92-9C49-51D726D8748CQ35244647-C27F732E-F930-4B21-87C7-4A3CF6F5AD44Q35565550-D63B9F78-C3D2-4BB6-BC98-87B0D3E744EEQ35875509-4F8ADCA6-287A-41EA-9F42-E34267C8D621Q35893083-FDD28668-091A-43D8-8D92-39100514C052Q36170506-EC054351-9AE8-4F16-BA5A-0C7A43BF9B4FQ36469613-AAB7751E-3231-455D-A897-80E46B31F986Q36852546-86396839-AEBE-427B-96EC-C03BFE967A1EQ37104389-77FA0593-13F0-41F1-9A42-E1CF0ACCEF72Q37264838-6BE6D6AD-AFCD-4A53-8930-A496D4E032E1Q37296564-F2468771-3B6E-4395-BEA0-138BA61E5116Q37367885-1B77D7AD-5081-43CF-AC05-26AF3A8DFECCQ37563016-5C51FE1F-015E-4D1B-A0D3-EDA9DD6CE69BQ38003324-FBBD3998-B385-47AD-83C0-E2792F544A08Q38482485-0BCBF4A5-CC0A-4093-95F0-BBD574ECE531Q38935459-20A33652-D980-4481-AC97-E0478EB2BEBEQ40063278-90580042-D6A7-4A43-8F87-41A82AE406B2Q41492477-81AD39AE-E851-48C1-A069-7B35DA218402Q41520155-9661D33A-9815-4554-9A11-3FFEB6322DF9Q41699341-EAB1B504-8909-4249-8F2F-06DD9A219A56Q41949365-66FBE684-8286-4DF0-BC3D-E0F34DB27F8CQ45184240-18218580-81C8-4FEC-9EF6-76C1EE8E9553Q45895881-39FC5DA8-4294-4ECB-8251-D4C7B24D0C1CQ47102338-A3616F91-6C1D-4D27-B6CA-E4F6C1A2591C
P2860
Neutralization of tumor necrosis factor in preclinical models of sepsis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Neutralization of tumor necrosis factor in preclinical models of sepsis.
@ast
Neutralization of tumor necrosis factor in preclinical models of sepsis.
@en
type
label
Neutralization of tumor necrosis factor in preclinical models of sepsis.
@ast
Neutralization of tumor necrosis factor in preclinical models of sepsis.
@en
prefLabel
Neutralization of tumor necrosis factor in preclinical models of sepsis.
@ast
Neutralization of tumor necrosis factor in preclinical models of sepsis.
@en
P1433
P1476
Neutralization of tumor necrosis factor in preclinical models of sepsis.
@en
P2093
John C Marshall
José A Lorente
P304
P356
10.1097/01.SHK.0000191343.21228.78
P478
24 Suppl 1
P577
2005-12-01T00:00:00Z